Alzheimer Disease: all 3,765 studies

Page 37 of 38. Open to participants first (881), then studies with results posted, then the rest; newest registration first within each.

• Project COPE:Managing Dementia at HomeCompletedNCT00259454Phase 3
• Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's DiseaseCompletedNCT00257673Phase 2
• Improving Mood and Behavior in Assisted Living Residents Through Skills Training for Their CaregiversCompletedNCT00255866Phase 2/3
• Apathy Associated With Alzheimer's DiseaseCompletedNCT00254033Phase 4
• A Study of the Safety and Effectiveness of a Flexible Dose of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's DiseaseCompletedNCT00253227Phase 3
• Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer's Disease: Safety and Efficacy of a Controlled-Release FormulationCompletedNCT00253214Phase 3
• A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's DiseaseCompletedNCT00253201Phase 3
• A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's DiseaseCompletedNCT00253188Phase 3
• A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Behavioral Disturbances in Patients With DementiaCompletedNCT00253123Phase 3
• A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With DementiaCompletedNCT00249158Phase 3
• A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With DementiaCompletedNCT00249145Phase 3
• Care Management for Patients With Alzheimer Disease and Their Family CaregiversCompletedNCT00246896Not applicable
• Side Effects of Newer Antipsychotics in Older AdultsCompletedNCT00245206Phase 4
• Effects of LY450139 Dihydrate on Subjects With Mild to Moderate Alzheimer's DiseaseCompletedNCT00244322Phase 2
• Influence of Age on Hemispheric Lateralization of Language : a Longitudinal StudyCompletedNCT00241293
• MIRAGE: Multi-Institutional Research in Alzheimer's Genetic EpidemiologyCompletedNCT00239759
• BONSAI: Biomarkers of Nonsteroidal Anti-InflammatoriesStatus unknownNCT00239746Phase 1
• A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive ImpairmentCompletedNCT00236574Phase 3
• A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive ImpairmentCompletedNCT00236431Phase 3
• Rivastigmine Monotherapy and Combination Therapy With Memantine in Patients With Moderately Severe Alzheimer's Disease Who Failed to Benefit From Previous Cholinesterase Inhibitor TreatmentCompletedNCT00234637Phase 4
• Quetiapine for the Treatment of Insomnia in Alzheimer's DiseaseStatus unknownNCT00232570Not applicable
• ALADDIN Study - Phase III: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (VP-AD-301)CompletedNCT00231946Phase 3
• EARTH 413: A Study of Aricept in Hispanic Patients With Mild to Moderate Alzheimer's Disease (AD)CompletedNCT00230568Phase 4
• Study of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer's Disease, Vascular Dementia, and Mixed Vascular and Alzheimer's DementiaStatus unknownNCT00229333Phase 4
• A Dose Ranging Study To Investigate The Efficacy And Safety Of SB-742457 In Alzheimer's DiseaseCompletedNCT00224497Phase 2
• An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's DiseaseCompletedNCT00219232Phase 3
• European Study of 3APS in Mild to Moderate Alzheimer's Disease PatientsStatus unknownNCT00217763Phase 3
• Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled StudyCompletedNCT00216593Phase 3
• The Efficacy of Galantamine on the Attention and the Frontal Function of the Patients With Dementia of Alzheimer TypeCompletedNCT00216515Phase 4
• A Study of the Safety and Effectiveness of Galantamine in Patients With Alzheimer's DiseaseCompletedNCT00216502Phase 3
• OmegAD (Omega-3 and Alzheimer's Disease)CompletedNCT00211159Not applicable
• Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body DementiaCompletedNCT00209456Phase 3
• A Comparison of Two Standard Therapies in the Management of Dementia With AgitationCompletedNCT00208819Phase 4
• Positron Emission Tomography of Amyloid in Alzheimer's DiseaseSuspendedNCT00205621Phase 1
• TNF-Alpha Inhibition for Treatment of Alzheimer's DiseaseCompletedNCT00203359Phase 1
• TNF-Alpha Inhibition for Treatment of Alzheimer's DiseaseCompletedNCT00203320Phase 1
• Double Blind Study of Trp01 in Patients With Alzheimer's DiseaseCompletedNCT00202124Phase 4
• The Serotonergic Transmitter System in Dementia and Affective DisordersStatus unknownNCT00192998
• Pain Perception in Alzheimer's DiseaseStatus unknownNCT00192816
• Adding Atomoxetine To Standard Medication Treatment In Patients With Alzheimer's DiseaseCompletedNCT00191009Phase 2/3
• AIDMA: A Psycho-educational Program Designed to Support and Train Carers of Alzheimer's Disease (AD) PatientsCompletedNCT00190372Not applicable
• Donepezil Treatment of Psychotic Symptoms in Dementia PatientsStatus unknownNCT00190021Phase 3
• Using Behavioral Programs to Treat Sleep Problems in Individuals With Alzheimer's DiseaseCompletedNCT00183378Not applicable
• Alzheimer's Caregiver Communication StudyCompletedNCT00182988
• PACT: Providers and Alzheimer's Caregivers TogetherCompletedNCT00182897Not applicable
• Coordinating Center for Enhancing ADRD CaregivingCompletedNCT00178165Not applicable
• Coordinating Center for Caregiver Intervention TrialCompletedNCT00177489Not applicable
• Safety Study of Passive Immunization for Patients With Mild to Moderate Alzheimer's DiseaseStatus unknownNCT00174525Phase 2
• MRS and DTI of White Matter in Alzheimer's DiseaseStatus unknownNCT00172900
• Correlation Between Regional Brain Volume and Response to Donepezil Treatment in AD PatientsTerminatedNCT00165750Phase 4
• Alzheimer's Disease Long-term Follow-up Study (ALF Study)CompletedNCT00165724Phase 4
• A Multi-Center, Randomized, Double-Blind, Parallel Group Study With 3 Groups Receiving Placebo, 5 mg of E2020 and 10 mg of E2020CompletedNCT00165659Phase 2
• A Pilot Study of Curcumin and Ginkgo for Treating Alzheimer's DiseaseCompletedNCT00164749Phase 1/2
• Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's TypeTerminatedNCT00160147Phase 3
• Efficacy and Safety Study of DCB-AD1 in Patients With Mild to Moderate Alzheimer's DiseaseStatus unknownNCT00154635Phase 2
• An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's TypeCompletedNCT00153010Phase 2
• To Evaluate the Safety and Effectiveness of Atorvastatin Plus a Cholinesterase Inhibitor in AD Patients.CompletedNCT00151502Phase 3
• Study Evaluating Lecozotan SR in Mild to Moderate Alzheimer's Disease (AD)CompletedNCT00151398Phase 2
• Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)CompletedNCT00151333Phase 2
• Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive ImpairmentCompletedNCT00149175
• Systematic Care for Informal Caregivers of Dementia Patients: An Efficient Approach?CompletedNCT00147693Not applicable
• Tricaprilin in Mild to Moderate Alzheimer's DiseaseCompletedNCT00142805Phase 2
• CALM-ADStatus unknownNCT00142324Phase 4
• A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's PatientsCompletedNCT00141661Phase 2
• Safety and Effect on Memory of PYM50028 in Mild Alzheimer's DiseaseCompletedNCT00130429Phase 2
• Testing the Effectiveness of Telephone Support for Dementia CaregiversCompletedNCT00119561Not applicable
• Anti-Oxidant Treatment of Alzheimer's DiseaseCompletedNCT00117403Phase 1
• AAB-001 in Patients With Mild to Moderate Alzheimer's DiseaseCompletedNCT00112073Phase 2
• Effects of Sage on Memory and Mental Performance in Alzheimer's Disease PatientsCompletedNCT00110552Phase 1
• ADNI: Alzheimer's Disease Neuroimaging InitiativeCompletedNCT00106899
• Telehealth Education Program for Caregivers of Veterans With DementiaCompletedNCT00105638Not applicable
• Memory Aid for Informed Consent in Alzheimer's ResearchCompletedNCT00105612Not applicable
• Efficacy Study of MPC-7869 to Treat Patients With Alzheimer'sCompletedNCT00105547Phase 3
• Mifepristone as Adjunctive Therapy in Alzheimer's DiseaseTerminatedNCT00105105Phase 2
• Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's DiseaseCompletedNCT00104442Phase 4
• Rasagiline 1 mg and 2 mg Added to Aricept 10 mg Daily in Patients With Mild to Moderate Alzheimer's Disease (AD)CompletedNCT00104273Phase 2
• Study of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's TypeCompletedNCT00104013Phase 3
• 18-Month Study of the Efficacy of Xaliproden (SR57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's TypeCompletedNCT00103649Phase 3
• Safety Study of PPI-1019 in Subjects With Mild-Moderate Alzheimer's DiseaseCompletedNCT00100334Phase 1/2
• Safety Study of PPI-1019 in Patients With Mild-Moderate Alzheimer's DiseaseCompletedNCT00100282Phase 1
• Curcumin in Patients With Mild to Moderate Alzheimer's DiseaseCompletedNCT00099710Phase 2
• Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's DiseaseCompletedNCT00099242Phase 3
• An Evaluation of the Safety and Efficacy of Memantine in Agitated Patients With Moderate to Severe Alzheimer's DiseaseCompletedNCT00097916Phase 3
• Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's DiseaseCompletedNCT00096473Phase 3
• Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With DementiaCompletedNCT00095719Phase 3
• Biomarkers and Early Alzheimer's DiseaseStatus unknownNCT00094952
• Predictors of Cognitive Decline in Normal AgingStatus unknownNCT00094939
• PET Changes in Alzheimer's Disease (AD)Status unknownNCT00094913
• SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD)CompletedNCT00093951Phase 2
• The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's DiseaseCompletedNCT00090116Phase 3
• Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IICompletedNCT00089882
• Treatment Study of Frontotemporal DementiaCompletedNCT00088751
• Evaluation of 3APS in Patients With Mild to Moderate Alzheimer's DiseaseStatus unknownNCT00088673Phase 3
• Effect of Lithium and Divalproex in Alzheimer's DiseaseCompletedNCT00088387Phase 2
• CERE-110 in Subjects With Mild to Moderate Alzheimer's DiseaseCompletedNCT00087789Phase 1
• A Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate Alzheimer's DiseaseTerminatedNCT00087724Phase 2
• Huperzine A in Alzheimer's DiseaseCompletedNCT00083590Phase 2
• Effects of ONO-2506PO in Patients With Alzheimer's DiseaseCompletedNCT00083421Phase 2
• Safety and Tolerability Study of Extended Release (ER) Galantamine in Alzheimer's DiseaseCompletedNCT00082602Phase 3
• Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 StudyCompletedNCT00076440Phase 2

← Alzheimer Disease overview